Summary
The objective of this study was to compare the lifetime cost-effectiveness of HMG-CoA reductase inhibitors and fibrates for the treatment of hyperlipidemia. Estimates of lipid modification achieved due to drug therapy were based on published head-to-head comparisons of specific HMG-CoA reductase inhibitors and fibrates in randomized, double-blind studies. We used a validated coronary heart disease (CHD) prevention computer model to estimate the costs and benefits of lifelong lipid modification. The patients were middle-aged men and women who were free of CHD, with either primary type IIa or IIb hyperlipidemia. The intervention used were specific HMG-CoA reductase inhibitors and fibrates at several dosages, which reduced total cholesterol 11–34% and increased high-density lipoprotein cholesterol 1–29%. The main outcome measure was the cost per year of life saved after discounting benefits and costs by 5% annually. The lifetime cost effectiveness of HMG-CoA reductase inhibitors (fluvastatin, lovastatin, pravastatin, simvastatin) and fibrates (bezafibrate, fenofibrate, gemfibrozil) for the treatment of primary hyperlipidemia varied according to patient population, the effectiveness of each drug in modifying lipid levels, and the price of each drug. The estimates of cost per year of life saved for HMG-CoA reductase inhibitors range from $19,886 to $73,632, and $16,955 to $59,488 for fibrates according to gender and type of primary hyperlipidemia. Fluvastatin 20 mg/day was significantly more cost effective than gemfibrozil 1200 mg/day for male patients with type IIa hyperlipidemia. Simvastatin 17.3 mg/day or 20 mg/day yielded similar cost-effectiveness ratios compared with fibrates among type II hyperlipidemic patients. However, micronized fenofibrate was more cost effective than simvastatin 20 mg/day among type IIb patients. The cost effectiveness of lipid therapy varies widely and can be maximized by selecting specific drugs for specific lipid abnormalities.
Similar content being viewed by others
References
Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial Results. I: Reduction in incidence of coronary heart disease. JAMA 1984;251: 351–364.
Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial Results. II: The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 1984;251:365–374.
Stamler, J, Wentworth, D, Neaton, JD. Is the relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? JAMA 1986;256:2823–2828.
Tyroler, HA. Review of lipid-lowering clinical trials in relation to observational epidemiologic studies. Circulation 1987;76:515–522.
Frick, MH, Elo, O, Olli, E, et al. Helsinki Heart Study: Primary prevention trial with gemfibrozil in middle-age men with dyslipidemia. N Engl J Med 1987;317:1237–1245.
Grover, SA, Coupal, L, Fakhry, R, Suissa, S. Screening for hypercholesterolemia among Canadians: How much will it cost? Can Med Assoc J 1991;144:161–168.
Garber, AM, Sox, HCJr, Littenberg, B. Screening asymptomatic adults for cardiac risk factors: The serum cholesterol level. Ann Intern Med 1989;110:622–639.
Tood, PA, Goa, KL. Simvastatin: A review of its pharmacological properties and therapeutic potential in hypercholesterolemia. Drugs 1990;40:583–607.
Larsen, ML, Illingworth, DR. Drug treatment of dyslipoproteinemia. Med Clin North Am 1994;78:225–245.
Betteridge, DJ, Durrington, PN, Fairhurst, GJ, et al.. Comparison of lipid-lowering effects of low-dose fluvastatin and conventional-dose gemfibrozil in patients with primary hypercholesterolemia. Am J Med 1994;96:45S-54S.
Greten, H, Beil, FU, Schneider, J, et al. Treatment of primary hypercholesterolemia: Fluvastatin versus bezafibrate. Am J Med 1994;96:55S-63S.
Crepaldi, G, Baggio, G, Arca, M, et al. Pravastatin vs. gemfibrozil in the treatment of primary hypercholesterolemia. The Italian multicenter pravastatin study I. Arch Intern Med 1990;151:146–152.
Farnier, M, Bonnefous, F, Debbas, N, Irvine, A. Comparative efficacy and safety of micronized fenofibrate and simvastatin in patients with primary type IIa or IIb hyperlipidemia. Arch Intern Med 1994;154:441–449.
Wiklund, O, Angelin, B, Bergman, M, et al. Pravastatin and gemfibrozil alone and in combination for the treatment of hypercholesterolemia. Am J Med 1993;94:13–20.
Tikkanen, MJ, Helve, E, Jaattela, A, et al. Comparison between lovastatin and gemfibrozil in the treatment of primary hypercholesterolemia: The Finnish multicenter study. Am J Cardiol 1988;62:35J-43J.
Tikkanen, MJ, Bocanegra, TS, Walker, JF, Cook, T. Comparison of low-dose simvastatin and gemfibrozil in the treatment of elevated plasma cholesterol. A multicenter study. Am J Med 1989;87:47S-53S.
Ziegler, O, Drouin, P. Simvastatin-Fenofibrate Study Group. Safety, tolerability, and efficacy of simvastatin and fenofibrate—A multicenter study. Cardiology 1990;77:50–57.
Miele, NF, Page, D. Controversial costs of cocaine. JAMA 1992;267:507–508.
Canadian Heart Health Surveys: A profile of cardiovascular risk. Can Med Assoc J 1992;(suppl):28–36.
Ontario Ministry of Health. Schedule of Benefits: Physician Services, 1989. Toronto: Ontario Ministry of Health, 1989.
Régie d'Assurance Maladie du Québec. Manuel des Médecins Omnipraticiens RAMQ, Québec, Québec: Régie de l'Assurance-Maladie du Québec, 1989.
Régie d'Assurance Maladie du Québec. Manuel des Médecins Specialistes RAMQ. Québec, Québec: Régie de l'Assurance-Maladie du Québec, 1989.
Grover, SA, Abrahamowicz, M, Joseph, L, et al. The benefits of treating hyperlipidemia to prevent coronary heart disease: Estimating changes in life expectancy and morbidity. JAMA 1992;267:816–822.
Abbott, RD, McGee, D. The probability of developing certain cardiovascular disease in eight years at specified values of some characteristics. In: Kannel, WB, Wolf, PA, Garrison, RJ, eds. The Framingham Study: An Epidemiological Investigation of Cardiovascular Disease. Bethesda, MD: U.S. Government Printing Office, 1987, section 37. U.S. Department of Health, Education, and Welfare Publication no. NIH 87–2284.
Statistics Canada, Health Division. Life Tables, Canada, and Provinces, 1985–1987. Ottawa, Ontario: Vital Statistics and Diseases Registries Section, 1989. Formely catalogue no. 84–532.
Kannel, WB, Wolf, PA, Garrison, RJ. Survival following initial cardiovascular events: 30 years follow-up. In: The Framingham Study: An Epidemiological Investigation of Cardiovascular Disease. Bethesda, MD: National Heart, Lung, and Blood Institute, 1988, section 35. National Heart, Lung and Blood Institute publication no. NIH 88–2969.
Grover, SA, Coupal, L. Risk benefit assessment of drug treatment to prevent heart disease. Drug Safety 1994;10: 301–309.
Grover, SA, Coupal, L, Hu, X. Identifying adults at increased risk of coronary disease: How well do the current cholesterol guidelines work? JAMA 1995;274:801–806.
Manninen, V, Elo, MO, Frick, MH, et al. Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study. JAMA 1988;260:641–651.
Hamilton, HV, Racicot, FE, Zowall, H, Coupal, L, Grover, S. The cost-effectiveness of HMG-CoA reductase inhibitors to prevent coronary heart disease. Estimating the benefits of increasing HDL-C. JAMA 1995;273:1032–1038.
Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383–1389.
Shepherd, J, Cobbe, SM, Ford, I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Trials Group. N Engl J Med 1995;333:1301–1307.
Manninen, V, Tenkanen, L, Koskinen, P, et al. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Circulation 1992;85:37–45.
Frick, MH, Heinonen, OP, Huttunen, JK, et al. Efficacy of gemfibrozil in dyslipidaemic subjects with suspected heart disease. An ancillary study in the Helsinki Heart Study Frame Population. Ann Med 1993;25:41–45.
Smith, GD, Song, F, Sheldon, TA. Cholesterol lowering and mortality: The importance of considering initial level of risk. Br Med J 1993;306:1367–1373.
Gould, AL, Rossouw, JE, Santanello, NC, et al. Cholesterol reduction yields clinical benefit, a new look at old data. Circulation 1995;91:2274–2282.
Garber, AM, Browner, WS, Hulley, SB. Cholesterol screening in asymptomatic adults, revisited. Ann Intern Med 1996;124:518–531.
Newman, TB, Hulley, SB. Carcinogenicity of lipid lowering drug. JAMA 1996;275:55–60.
Roberts, SD, Maxwell, DR, Gross, TL. Cost-effective care of end-stage renal disease: A billion dollar question. Ann Intern Med 1980;92:243.
Garner, TI, Dardis, R. Cost-effectiveness analysis of end-stage renal disease treatments. Med Care 1987;25:25–34.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Perreault, S., Hamilton, V.H., Lavoie, F. et al. A head-to-head comparison of the cost effectiveness of HMG-CoA reductase inhibitors and fibrates in different types of primary hyperlipidemia. Cardiovasc Drug Ther 10, 787–794 (1997). https://doi.org/10.1007/BF00053037
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00053037